PF-07934040
- Generic Name
- PF-07934040
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalColorectal Neoplasms
- Interventions
- Combination Product: GemcitabineCombination Product: CetuximabCombination Product: FluorouracilCombination Product: PembrolizumabCombination Product: Nab-paclitaxelCombination Product: OxaliplatinCombination Product: pemetrexedCombination Product: LeucovorinCombination Product: CisplatinCombination Product: BevacizumabCombination Product: PaclitaxelCombination Product: Carboplatin
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 330
- Registration Number
- NCT06447662
- Locations
- 🇺🇸
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora, Colorado, United States
🇺🇸Highlands Oncology Group, PA, Rogers, Arkansas, United States
🇺🇸City of Hope Investigational Drug Service (IDS), Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath